<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03055767</url>
  </required_header>
  <id_info>
    <org_study_id>UCIANES09</org_study_id>
    <nct_id>NCT03055767</nct_id>
  </id_info>
  <brief_title>Effectiveness of Onabotulinumtoxin A (Botox) in Pediatric Patients Experiencing Migraines: A Study in the Pediatric Pain Population</brief_title>
  <official_title>Effectiveness of Onabotulinumtoxin A (Botox) in Pediatric Patients Experiencing Migraines: A Randomized Double Blinded Placebo Cross-over Study in the Pediatric Pain Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Society of Regional Anesthesia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the research is to examine the outcomes of pediatric patients receiving
      Botulinum toxin type A (Botox ®) for the treatment of migraine. There is limited literature
      on the effectiveness of Botox ® in the treatment of chronic neurological pain in pediatric
      patients, specifically in the treatment of migraines.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Medical Literature approximates one in three children will experience chronic headaches in
      their lifetime, which increases as children reach adolescence. Migraines make up nearly 60%
      of all visits to a pediatric headache specialist. Studies have demonstrated the negative
      impact of having childhood migraine on overall quality of life is similar to pediatric
      cancer, heart disease and rheumatic disease. As the frequency of migraine attacks increase,
      so does proportionally the child's disability in lost school time and family and social
      interactions, all of which may lead in turn to economic disability. Studies estimate the
      health care costs are 70% higher for a family with a migraine than a non-migraine affected
      family, and direct medical costs for children with migraine are reported to be similar to
      those for adults. A study published in JAMA 2003 found that health care costs, work-related
      disability for parents and lost educational opportunity for the child leads to an annual
      economic impact in the US of approximately $36 billion due to both direct medical costs and
      lost productivity into adulthood.

      Onaboutlinum (BOTOX) is currently FDA approved as a very successful treatment to prevent
      migraines in adults, however not yet children. Current treatments for migraine in children
      appear to be insufficient. No trials currently exist in literature prospectively studying
      onabotulinumtoxinA for efficacy and/or safety for indication of pediatric migraine, although
      significant contributions have been made by retrospective case series over the last 10 years.

      This research will be the first investigator-initiated study to study BOTOX (R) in children
      prospectively in a randomized controlled placebo, cross-over study. The overriding rationale
      is to demonstrate efficacy, tolerability and safety of onabotulinumtoxinA for pediatric
      migraine and thereby potentially hasten the lengthy process to evaluate BOTOX® for approval
      in the pediatric population.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain scores (Intensity)</measure>
    <time_frame>12 months</time_frame>
    <description>(standardized numerical rating scale);</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in duration of migraine episode</measure>
    <time_frame>12 months</time_frame>
    <description>(chart history)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Migraine</measure>
    <time_frame>12 months</time_frame>
    <description>(chart history);</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disability and Functionality</measure>
    <time_frame>12 months</time_frame>
    <description>(chart history); PediMIDAS scoring</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid Consumption</measure>
    <time_frame>12 months</time_frame>
    <description>Amount of opioid medication consumed (chart history)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of benefit of onabotulinumtoxinA therapy</measure>
    <time_frame>12 months</time_frame>
    <description>chart history</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Associated side effects</measure>
    <time_frame>12 months</time_frame>
    <description>incidence of nausea, vomiting, food intake, diarrhea, constipation, anxiety, depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event (AE) related to onabotulinumtoxin A</measure>
    <time_frame>12 months</time_frame>
    <description>(chart history)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue medication use/change</measure>
    <time_frame>12 months</time_frame>
    <description>chart review</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital and Emergency Department (ED) utilization</measure>
    <time_frame>12 months</time_frame>
    <description>chart review</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Current medication use</measure>
    <time_frame>12 months</time_frame>
    <description>Increase, Decrease or no change in concomitant headache medication</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Migraine Disorders</condition>
  <condition>Headache, Migraine</condition>
  <condition>Pediatrics</condition>
  <arm_group>
    <arm_group_label>OnabotulinumtoxinA/Saline Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The AB subject group will receive OnabotulinumtoxinA in the first treatment and saline placebo in the second.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Placebo/OnabotulinumtoxinA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The BA subject group will receive saline and then Onabotulinumtoxin. A.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OnabotulinumtoxinA</intervention_name>
    <description>The AB subject group will receive OnabotulinumtoxinA in the first treatment and saline placebo in the second.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.</description>
    <arm_group_label>OnabotulinumtoxinA/Saline Placebo</arm_group_label>
    <arm_group_label>Saline Placebo/OnabotulinumtoxinA</arm_group_label>
    <other_name>Botox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo (Saline)</intervention_name>
    <description>The BA subject group will receive saline and then Onabotulinumtoxin. A.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.</description>
    <arm_group_label>OnabotulinumtoxinA/Saline Placebo</arm_group_label>
    <arm_group_label>Saline Placebo/OnabotulinumtoxinA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children aged 8 - 17 years of age with a history of migraine meeting the criteria
             established in ICHD-II (2004), Section 1. Patients will provide at least 28-day
             baseline data in the form in the daily diary and must have at least 15 days of
             reported headache during this period, with at least 4 distinct episodes lasting at
             least 4 hours each.

        Exclusion Criteria:

          -  Previous use of botulinum toxin of any serotype for any reason

          -  Pregnancy.

          -  Diagnosis of Myasthenia gravis, Eaton Lambert Syndrome, Amyotrophic Lateral Sclerosis

          -  Treatment of headache using acupuncture, transcutaneous electrical stimulation (TENS),
             cranial traction, dental splints, or injection of anesthetics/steroids within 4 weeks
             prior to the week of screening visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shalini S Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Clinical Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shalini S Shah, MD</last_name>
    <phone>714-456-5059</phone>
    <email>ssshah1@uci.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joseph B Rinehart, MD</last_name>
    <phone>714-456-5059</phone>
    <email>jrinehar@uci.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gottschalk Medical Plaza</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shalini S Shah, MD</last_name>
      <phone>714-456-5059</phone>
      <email>ssshah1@uci.edu</email>
    </contact>
    <contact_backup>
      <last_name>Michael-David Calderon, BS</last_name>
      <phone>714-456-7800</phone>
      <phone_ext>120-2464</phone_ext>
      <email>mccalder@uci.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UC Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael-David Calderon, BS</last_name>
      <phone>714-456-7800</phone>
      <phone_ext>2464</phone_ext>
      <email>mccalder@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Shalini Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Rinehart, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, VanDenburgh AM, Nolan ME, Turkel CC. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011 Oct;51(9):1358-73. doi: 10.1111/j.1526-4610.2011.01990.x. Epub 2011 Aug 29.</citation>
    <PMID>21883197</PMID>
  </reference>
  <reference>
    <citation>Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF; PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010 Jun;50(6):921-36. doi: 10.1111/j.1526-4610.2010.01678.x. Epub 2010 May 7.</citation>
    <PMID>20487038</PMID>
  </reference>
  <reference>
    <citation>Ahmed K, Oas KH, Mack KJ, Garza I. Experience with botulinum toxin type A in medically intractable pediatric chronic daily headache. Pediatr Neurol. 2010 Nov;43(5):316-9. doi: 10.1016/j.pediatrneurol.2010.06.001.</citation>
    <PMID>20933173</PMID>
  </reference>
  <reference>
    <citation>Bonfert M, Straube A, Schroeder AS, Reilich P, Ebinger F, Heinen F. Primary headache in children and adolescents: update on pharmacotherapy of migraine and tension-type headache. Neuropediatrics. 2013 Feb;44(1):3-19. doi: 10.1055/s-0032-1330856. Epub 2013 Jan 9. Review.</citation>
    <PMID>23303551</PMID>
  </reference>
  <reference>
    <citation>Brodsky JR, Cusick BA, Zhou G. Evaluation and management of vestibular migraine in children: Experience from a pediatric vestibular clinic. Eur J Paediatr Neurol. 2016 Jan;20(1):85-92. doi: 10.1016/j.ejpn.2015.09.011. Epub 2015 Oct 22.</citation>
    <PMID>26521123</PMID>
  </reference>
  <reference>
    <citation>Chan VW, McCabe EJ, MacGregor DL. Botox treatment for migraine and chronic daily headache in adolescents. J Neurosci Nurs. 2009 Oct;41(5):235-43.</citation>
    <PMID>19835236</PMID>
  </reference>
  <reference>
    <citation>Hermann C, Kim M, Blanchard EB. Behavioral and prophylactic pharmacological intervention studies of pediatric migraine: an exploratory meta-analysis. Pain. 1995 Mar;60(3):239-55.</citation>
    <PMID>7596620</PMID>
  </reference>
  <reference>
    <citation>Hershey AD, Powers SW, Coffey CS, Eklund DD, Chamberlin LA, Korbee LL; CHAMP Study Group. Childhood and Adolescent Migraine Prevention (CHAMP) study: a double-blinded, placebo-controlled, comparative effectiveness study of amitriptyline, topiramate, and placebo in the prevention of childhood and adolescent migraine. Headache. 2013 May;53(5):799-816. doi: 10.1111/head.12105. Epub 2013 Apr 17.</citation>
    <PMID>23594025</PMID>
  </reference>
  <reference>
    <citation>Jacobs H, Gladstein J. Pediatric headache: a clinical review. Headache. 2012 Feb;52(2):333-9. doi: 10.1111/j.1526-4610.2011.02086.x. Epub 2012 Jan 30. Review. Erratum in: Headache. 2012 Mar;52(3):527. Dosage error in article text.</citation>
    <PMID>22288433</PMID>
  </reference>
  <reference>
    <citation>Kabbouche M, O'Brien H, Hershey AD. OnabotulinumtoxinA in pediatric chronic daily headache. Curr Neurol Neurosci Rep. 2012 Apr;12(2):114-7. doi: 10.1007/s11910-012-0251-1.</citation>
    <PMID>22274570</PMID>
  </reference>
  <reference>
    <citation>Kacperski J, Hershey AD. Preventive drugs in childhood and adolescent migraine. Curr Pain Headache Rep. 2014 Jun;18(6):422. doi: 10.1007/s11916-014-0422-7. Review.</citation>
    <PMID>24760491</PMID>
  </reference>
  <reference>
    <citation>Yonker M, Mangum T. Migraine management in children. Curr Neurol Neurosci Rep. 2015 May;15(5):20. doi: 10.1007/s11910-015-0540-6. Review.</citation>
    <PMID>25772998</PMID>
  </reference>
  <reference>
    <citation>Tajti J, Szok D, Csáti A, Vécsei L. Prophylactic Drug Treatment of Migraine in Children and Adolescents: An Update. Curr Pain Headache Rep. 2016 Jan;20(1):1. doi: 10.1007/s11916-015-0536-6. Review.</citation>
    <PMID>26695061</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2017</study_first_submitted>
  <study_first_submitted_qc>February 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2017</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Shalini Suresh Shah</investigator_full_name>
    <investigator_title>Assistant Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

